目次

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MOLECULAR CYTOGENETICS MARKET SIZE ESTIMATION, 2024
2.2.1.1 Revenue share analysis (bottom-up approach)
2.2.1.2 Secondary data & primary interviews
2.2.1.2.1 Insights of primary experts
2.2.1.3 MnM repository analysis
2.2.2 SEGMENTAL MARKET ASSESSMENT: TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
3.3 DISRUPTIVE TRENDS SHAPING MOLECULAR CYTOGENETICS MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS
4.1 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION AND COUNTRY
4.2 MOLECULAR CYTOGENETICS MARKET SHARE, BY END USER, 2024
4.3 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS
4.6 VC/PRIVATE EQUITY INVESTMENT TRENDS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancement and adoption of high-resolution techniques
5.2.1.2 Growing focus on targeted cancer treatment
5.2.1.3 Increasing penetration of molecular cytogenetics in clinical pathological testing
5.2.2 RESTRAINTS
5.2.2.1 High cost of advanced instruments
5.2.2.2 Unfavorable reimbursement scenario for advanced diagnostic tests
5.2.3 OPPORTUNITIES
5.2.3.1 Untapped emerging markets
5.2.4 CHALLENGES
5.2.4.1 Transition from FISH to array-based molecular cytogenetic techniques in diagnostic and research communities
5.3 UNMET NEEDS & WHITE SPACES

6 INDUSTRY TRENDS
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
6.2 CASE STUDY ANALYSIS
6.2.1 MOSAIC TETRASOMY 9P TO BE DETECTED BY CNV-SEQ IN PRENATAL DIAGNOSIS
6.2.2 PRENATAL DETECTION OF 15Q21.3 AND 16P11.2 MICRODUPLICATION SYNDROMES USING CNV-SEQ AND WES
6.2.3 INTEGRATED CNV-SEQ AND KARYOTYPING IN LARGE PRENATAL COHORT FOR CHROMOSOMAL ABNORMALITY DETECTION
6.3 TECHNOLOGY ANALYSIS
6.3.1 KEY TECHNOLOGIES
6.3.1.1 Optical genome mapping
6.3.1.2 Next-generation sequencing
6.3.2 COMPLEMENTARY TECHNOLOGIES
6.3.2.1 CRISPR-based editing
?
6.4 PRICING ANALYSIS
6.4.1 AVERAGE SELLING PRICE TREND OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER, 2022-2024
6.4.2 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022-2024
6.5 PATENT ANALYSIS
6.5.1 METHODOLOGY
6.5.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
6.5.3 LIST OF KEY PATENTS
6.6 TRADE ANALYSIS
6.6.1 IMPORT DATA FOR HS CODE 3822.00, 2020-2024
6.6.2 EXPORT DATA FOR HS CODE 3822.00, 2020-2024
6.7 VALUE CHAIN ANALYSIS
6.8 ECOSYSTEM ANALYSIS
6.8.1 ROLE IN ECOSYSTEM
6.8.2 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
6.9 PORTER’S FIVE FORCES ANALYSIS
6.9.1 INTENSITY OF COMPETITIVE RIVALRY
6.9.2 BARGAINING POWER OF SUPPLIERS
6.9.3 BARGAINING POWER OF BUYERS
6.9.4 THREAT OF SUBSTITUTES
6.9.5 THREAT OF NEW ENTRANTS
6.10 KEY STAKEHOLDERS & BUYING CRITERIA
6.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.10.2 KEY BUYING CRITERIA
6.11 TARIFF & REGULATORY ANALYSIS
6.11.1 TARIFF DATA FOR HS CODES 9027.50.80 AND 3822.00
6.11.1.1 US
6.11.1.2 European Union
6.11.1.3 Asia Pacific
6.11.2 REGULATORY LANDSCAPE
6.11.2.1 North America
6.11.2.1.1 US
6.11.2.1.2 Canada
6.11.2.2 Europe
6.11.2.3 Asia Pacific
6.11.2.3.1 Japan
6.11.2.3.2 China
6.11.2.3.3 India
6.11.2.4 Latin America
6.11.2.4.1 Brazil
?
6.11.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.11.4 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
6.12 KEY CONFERENCES & EVENTS, 2025-2026
6.13 INVESTMENT & FUNDING SCENARIO
6.14 IMPACT OF AI/GEN AI ON MOLECULAR CYTOGENETICS MARKET
6.15 IMPACT OF 2025 US TARIFF ON MOLECULAR CYTOGENETICS MARKET
6.15.1 INTRODUCTION
6.15.2 KEY TARIFF RATES
6.15.3 PRICE IMPACT ANALYSIS
6.15.4 KEY IMPACT ON COUNTRIES/REGIONS
6.15.4.1 North America
6.15.4.1.1 US
6.15.4.2 Europe
6.15.4.3 Asia Pacific
6.15.5 IMPACT OF END-USE INDUSTRIES
6.15.5.1 Clinical & diagnostic laboratories
6.15.5.2 Academic & research institutes
6.15.5.3 Pharmaceutical & biotechnology companies

7 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE
7.1 INTRODUCTION
7.2 KITS & REAGENTS
7.2.1 TESTING KITS
7.2.1.1 Standardized and integrated kit workflows to propel market growth
7.2.2 PROBES
7.2.2.1 Advances in oligonucleotide probe chemistry, multiplexing, and regulatory-driven product modernization to boost market
7.2.3 FLUORESCENT AFFINITY REAGENTS
7.2.3.1 Improved fluorochrome chemistry and pre-validated conjugates paired with advanced spectral imaging to drive growth
7.2.4 OTHER KITS & REAGENTS
7.3 CONSUMABLES
7.3.1 STANDARDIZATION AND EXPANDING CLINICAL APPLICATIONS TO PROMOTE MARKET GROWTH
7.4 INSTRUMENTS
7.4.1 AUTOMATION, AI-ENABLED IMAGING, AND INTEGRATED PLATFORMS TO DRIVE MARKET
7.5 SOFTWARE & SERVICES
7.5.1 AI INTEGRATION, WORKFLOW STANDARDIZATION, AND CLOUD-ENABLED DATA MANAGEMENT TO DRIVE MARKET
?

8 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE
8.1 INTRODUCTION
8.2 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
8.2.1 INTEGRATION OF FISH AND ADVANCED IMAGING TECHNOLOGIES TO DRIVE GROWTH
8.3 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION (ACGH)
8.3.1 BETTER CLINICAL ACCEPTANCE AND IMPROVED TECHNOLOGICAL INTEGRATION TO PROPEL MARKET GROWTH
8.4 CHROMOGENIC IN SITU HYBRIDIZATION (CISH)
8.4.1 ENHANCED PROBE TECHNOLOGY AND BETTER WORKFLOW AUTOMATION TO BOOST MARKET GROWTH
8.5 OTHER TECHNIQUES

9 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 GENETIC DISORDERS
9.2.1 EXPANDED CLINICAL GUIDELINES AND IMPROVED CMA/FISH TECHNOLOGIES TO PROPEL MARKET GROWTH
9.3 CANCER
9.3.1 RISING CANCER RESEARCH AND INCREASING USE OF AUTOMATED CYTOGENETIC PLATFORMS TO DRIVE MARKET
9.4 PERSONALIZED MEDICINE
9.4.1 STRATEGIC COLLABORATIONS AND BIOMARKER-DRIVEN CYTOGENETIC TESTING TO ACCELERATE MARKET GROWTH
9.5 OTHER APPLICATIONS

10 MOLECULAR CYTOGENETICS MARKET, BY END USER
10.1 INTRODUCTION
10.2 CLINICAL & DIAGNOSTIC LABORATORIES
10.2.1 INVESTMENT IN AUTOMATION AND INDUSTRY PARTNERSHIPS TO DRIVE MARKET GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 STRATEGIC ACADEMIA-INDUSTRY COLLABORATIONS TO AUGMENT MARKET GROWTH
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.4.1 STRATEGIC ACQUISITIONS AND PRECISION MEDICINE INTEGRATION TO FUEL MARKET GROWTH
10.5 OTHER END USERS
?

11 MOLECULAR CYTOGENETICS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 US to dominate North American molecular cytogenetics market during study period
11.2.3 CANADA
11.2.3.1 Increasing cancer burden and expanding application of cytogenetics technology in oncology to drive market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Dynamic convergence of research excellence, clinical adoption, and industry collaboration to augment market growth
11.3.3 UK
11.3.3.1 Strong governmental support for genomics research and advanced healthcare infrastructure to aid market growth
11.3.4 FRANCE
11.3.4.1 Increasing government investment in pharmaceutical industry to support market growth
11.3.5 ITALY
11.3.5.1 Rising research activities in pharma R&D to boost market growth
11.3.6 SPAIN
11.3.6.1 Well-established network of research centers and universities to boost clinical and diagnostic research
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Development of advanced healthcare infrastructure and government support for genomics research to propel growth
11.4.3 JAPAN
11.4.3.1 Technological adoption and increased clinical programs to favor market growth
11.4.4 INDIA
11.4.4.1 Rising awareness of cancer and genetic disorders to support market growth
11.4.5 AUSTRALIA
11.4.5.1 Progressive translational research, advanced diagnostic integration, and cross-institutional collaborations to fuel growth
11.4.6 SOUTH KOREA
11.4.6.1 Technological innovation and high demand for precision medicines to aid market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Increased number of public-private collaborations to focus on strategic market expansions
11.5.3 MEXICO
11.5.3.1 Strengthening genomic infrastructure and technology integration to support market growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Kingdom of Saudi Arabia
11.6.2.1.1 Growing healthcare expenditure to boost market growth
11.6.2.2 UAE
11.6.2.2.1 Rising government support and incorporation of ISH technologies by hospitals to aid market growth
11.6.2.3 Rest of GCC countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING MARKET FOR PHARMACEUTICALS AND INCREASING DEMAND FOR GENETIC TESTING TO PROPEL GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION & FINANCIAL METRICS
12.5.1 FINANCIAL METRICS
12.5.2 COMPANY VALUATION
12.6 BRAND/PRODUCT COMPARISON
12.6.1 F. HOFFMANN-LA ROCHE LTD.
12.6.2 DANAHER CORPORATION
12.6.3 AGILENT TECHNOLOGIES, INC.
12.6.4 ABBOTT
12.6.5 THERMO FISHER SCIENTIFIC INC.
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Product & service footprint
12.7.5.4 Technique footprint
12.7.5.5 Application footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 F. HOFFMANN-LA ROCHE LTD.
13.1.1.1 Business overview
13.1.1.2 Products/Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches & approvals
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 DANAHER CORPORATION
13.1.2.1 Business overview
13.1.2.2 Products/Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
?
13.1.3 AGILENT TECHNOLOGIES, INC.
13.1.3.1 Business overview
13.1.3.2 Products/Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches
13.1.3.3.2 Deals
13.1.3.3.3 Other developments
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 ABBOTT
13.1.4.1 Business overview
13.1.4.2 Products/Services offered
13.1.4.3 MnM view
13.1.4.3.1 Key strengths
13.1.4.3.2 Strategic choices
13.1.4.3.3 Weaknesses & competitive threats
13.1.5 THERMO FISHER SCIENTIFIC INC.
13.1.5.1 Business overview
13.1.5.2 Products/Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches
13.1.5.3.2 Deals
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 ILLUMINA, INC.
13.1.6.1 Business overview
13.1.6.2 Products/Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Expansions
13.1.7 REVVITY
13.1.7.1 Business overview
13.1.7.2 Products/Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches
13.1.7.3.2 Deals
?
13.1.8 PACBIO
13.1.8.1 Business overview
13.1.8.2 Products/Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.8.3.2 Expansions
13.1.9 BIO-RAD LABORATORIES, INC.
13.1.9.1 Business overview
13.1.9.2 Products/Services offered
13.1.10 BIO-TECHNE
13.1.10.1 Business overview
13.1.10.2 Products/Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Product launches
13.1.10.3.2 Deals
13.1.11 GENE DX, LLC
13.1.11.1 Business overview
13.1.11.2 Products/Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Deals
13.1.12 INSIGHT MOLECULAR DIAGNOSTICS INC.
13.1.12.1 Business overview
13.1.12.2 Products/Services offered
13.1.13 BIOVIEW
13.1.13.1 Business overview
13.1.13.2 Products/Services offered
13.2 OTHER PLAYERS
13.2.1 OXFORD GENE TECHNOLOGY IP LIMITED
13.2.2 APPLIED SPECTRAL IMAGING
13.2.3 CYTOTEST INC.
13.2.4 KROMATID
13.2.5 GENIAL GENETIC SOLUTIONS LTD.
13.2.6 CYTOGNOMIX INC.
13.2.7 METASYSTEMS
13.2.8 SCIGENE CORPORATION
13.2.9 BIOMODAL
13.2.10 BIOCARE MEDICAL, LLC
13.2.11 BIODOT
13.2.12 ONCODNA
?

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS